Ondine Biomedical Inc.

Transaction in Own Shares • Aug 16, 2022

National Storage Mechanism | Additional information

RNS Number : 0948W

Ondine Biomedical Inc.

16 August 2022

Ondine Biomedical Inc.

("Ondine" or the "Company")

Ondine appoints RBC and Singer as joint brokers

Ondine Biomedical Inc. (AIM: OBI), a life sciences company which is a leader in antimicrobial photodisinfection technology, announces the appointment of RBC Capital Markets and Singer Capital Markets as the Company's joint brokers, effective immediately. 

Ends

For more information, please visit:  www.ondinebio.com or contact: 

Ondine Biomedical Inc.
Carolyn Cross, CEO	+1 604 669 0555
Strand Hanson Limited (Nominated and Financial Adviser)
James Harris, James Dance, Richard Johnson	+44 (0) 20 7409 3494
RBC Capital Markets
Rupert Walford, Kathryn Deegan	+44 (0) 20 7653 4000
Singer Capital Markets
Aubrey Powell, Asha Chotai	+44 (0)20 7496 3000
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	+44 (0) 77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company led by founder and CEO, Carolyn Cross. Ondine has developed a patented, photodisinfection technology platform used in treatment and prevention therapies for a broad-spectrum of pathogens - including multidrug-resistant strains. Photodisinfection is a targeted antimicrobial which uses non-thermal light to activate a photosensitive agent. In a few minutes, this light-based therapy destroys the pathogens through an oxidative burst without any impact on human tissue.

Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products include treatment of chronic rhinosinusitis, decolonization of infections in burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and most recently, the development of topical antiviral therapy for the upper respiratory tract to reduce viral titres and transmission of respiratory viruses (e.g., SARS-CoV-2, influenza, RSV, etc.). Ondine's technology is approved in a number of jurisdictions and has been awarded the CE mark, as well as Qualified Infectious Disease Product and Fast Track status in the US by the FDA.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPFLFVATLIELIF